LiberoThera has obtained commercial licenses from RIKEN for the membrane protein technologies and has established the ground-breaking drug discovery platform allowing to generate distinctive therapeutic pipelines.
LiberoThera is developing novel therapeutics, such as antibody drugs targeting GPCRs, for treatment of cancer and some other chronical diseases.
LiberoThera’s propriate drug discovery platform can be subjected for drug discovery research under collaboration.
